KORU Medical Systems Announces Agreement for Next-Generation Subcutaneous Immunoglobulin Infusion System
KORU Medical Systems (NASDAQ: KRMD) has announced a significant agreement with a global pharmaceutical company to develop and seek regulatory clearance for a next-generation subcutaneous immunoglobulin (SCIg) therapy infusion system. The project involves collaboration with SCHOTT Pharma and aims to create a platform infusion system compatible with both vial and prefilled syringe formats.
The innovative system will integrate KORU Medical's infusion technology with SCHOTT TOPPAC® prefillable polymer syringes (PFS). This development is expected to be the first of multiple joint projects with SCHOTT, focusing on providing a more convenient infusion experience for SCIg patients through an easy-to-use system that facilitates home therapy.
KORU Medical Systems (NASDAQ: KRMD) ha annunciato un'importante accordo con una casa farmaceutica globale per sviluppare e ottenere l'approvazione normativa di un sistema di infusione per la terapia a base di immunoglobuline sottocutanee (SCIg) di nuova generazione. Il progetto prevede la collaborazione con SCHOTT Pharma e mira a creare un sistema di infusione compatibile con formati sia di flaconcino che di siringa pre-riempita.
Il sistema innovativo integrerà la tecnologia di infusione di KORU Medical con le siringhe polimeriche pre-riempite SCHOTT TOPPAC®. Questo sviluppo è previsto come il primo di una serie di progetti congiunti con SCHOTT, concentrandosi sulla fornitura di un'esperienza di infusione più comoda per i pazienti SCIg attraverso un sistema facile da usare che facilita la terapia a casa.
KORU Medical Systems (NASDAQ: KRMD) ha anunciado un importante acuerdo con una compañía farmacéutica global para desarrollar y buscar la aprobación regulatoria para un sistema de infusión de terapia de inmunoglobulina subcutánea (SCIg) de próxima generación. El proyecto implica la colaboración con SCHOTT Pharma y tiene como objetivo crear un sistema de infusión compatible con formatos tanto de vial como de jeringa precargada.
El sistema innovador integrará la tecnología de infusión de KORU Medical con jeringas poliméricas precargadas SCHOTT TOPPAC®. Se espera que este desarrollo sea el primero de múltiples proyectos conjuntos con SCHOTT, centrados en proporcionar una experiencia de infusión más conveniente para los pacientes de SCIg a través de un sistema fácil de usar que facilite la terapia en casa.
KORU Medical Systems (NASDAQ: KRMD)는 글로벌 제약 회사와 협력하여 차세대 피하 면역글로불린(SCIg) 요법 주입 시스템을 개발하고 규제 승인을 받기 위한 중요한 계약을 발표했습니다. 이 프로젝트는 SCHOTT Pharma와 협력하여 바이알 및 미리 채워진 주사기 형식 모두와 호환되는 플랫폼 주입 시스템을 만드는 것을 목표로 하고 있습니다.
이 혁신적인 시스템은 KORU Medical의 주입 기술과 SCHOTT TOPPAC® 프리필 폴리머 주사기를 통합할 것입니다. 이 개발은 SCIg 환자들에게 좀 더 편리한 주입 경험을 제공하기 위한 여러 공동 프로젝트의 첫 번째로 예상되며, 사용하기 쉬운 시스템을 통해 가정 요법을 용이하게 할 수 있도록 합니다.
KORU Medical Systems (NASDAQ: KRMD) a annoncé un accord significatif avec une entreprise pharmaceutique mondiale pour développer et obtenir l'autorisation réglementaire d'un système d'infusion de thérapie à base d'immunoglobulines sous-cutanées (SCIg) de nouvelle génération. Le projet implique une collaboration avec SCHOTT Pharma et vise à créer un système d'infusion compatible avec des formats de flacons et de seringues pré-remplies.
Ce système innovant intégrera la technologie d'infusion de KORU Medical avec les seringues polymères pré-remplies SCHOTT TOPPAC®. Ce développement devrait être le premier d'une série de projets communs avec SCHOTT, visant à fournir une expérience d'infusion plus pratique pour les patients SCIg grâce à un système facile à utiliser qui facilite la thérapie à domicile.
KORU Medical Systems (NASDAQ: KRMD) hat eine bedeutende Vereinbarung mit einem globalen Pharmaunternehmen bekannt gegeben, um ein Infusionssystem für eine next-generation subkutane Immunglobulin (SCIg)-Therapie zu entwickeln und die behördliche Genehmigung zu beantragen. Das Projekt umfasst die Zusammenarbeit mit SCHOTT Pharma und zielt darauf ab, ein Infusionssystem zu schaffen, das sowohl mit Vial- als auch mit Fertigspritzenformaten kompatibel ist.
Das innovative System wird die Infusionstechnologie von KORU Medical mit den SCHOTT TOPPAC® vorgefüllten Polymer-Spritzen integrieren. Diese Entwicklung wird voraussichtlich das erste von mehreren gemeinsamen Projekten mit SCHOTT sein, die darauf abzielen, Patienten mit SCIg eine komfortablere Infusionserfahrung durch ein einfach zu bedienendes System zu bieten, das die häusliche Therapie erleichtert.
- Strategic partnership with a global pharmaceutical company
- Development of next-generation SCIg therapy infusion system
- Collaboration with SCHOTT Pharma for multiple future projects
- Product expansion to include both vial and prefilled syringe compatibility
- None.
Insights
The announced agreement represents a significant strategic advancement for KORU Medical Systems in the rapidly growing subcutaneous drug delivery market. The development of a next-generation SCIg infusion system that accommodates both vials and prefilled syringes positions KORU at the forefront of home infusion technology innovation.
The collaboration with SCHOTT Pharma, a global leader in pharmaceutical packaging, is particularly noteworthy. SCHOTT's TOPPAC® prefillable polymer syringes are widely used in the pharmaceutical industry and this partnership could potentially lead to KORU becoming the preferred delivery system provider for multiple drug manufacturers. The mention of 'multiple joint projects' suggests a broader strategic alliance that could significantly expand KORU's market reach.
From a market perspective, the global subcutaneous drug delivery devices market is experiencing robust growth, driven by:
- Increasing prevalence of chronic diseases requiring regular drug administration
- Growing preference for home-based healthcare solutions
- Rising demand for self-administration devices
- Shift towards patient-centric drug delivery systems
The development of a platform infusion system that can handle both traditional vials and modern prefilled syringes demonstrates strong market foresight. This dual compatibility reduces barriers to adoption and positions KORU to capture market share across both existing and new drug formulations. The agreement with a global pharmaceutical company suggests potential for significant revenue streams through both development fees and future commercial sales.
Additionally, the project will include a close collaboration with SCHOTT Pharma and is expected to be the first of multiple joint projects with SCHOTT, allowing KORU Medical to develop a platform infusion system that can integrate with both a vial and prefilled syringe. The innovative system will be developed using KORU Medical’s infusion technology along with SCHOTT TOPPAC® prefillable polymer syringes (PFS).
“This collaboration marks another milestone in our strategy to provide the most convenient infusion experience to SCIg patients,” said Linda Tharby, President and CEO of KORU Medical. “To receive the full benefit from innovative SCIg medications, including new formats like prefilled syringes, patients need an infusion system that is easy to use, fits into their lifestyles, and can efficiently deliver the drug they have been prescribed. This next-generation infusion system is intended to facilitate easier home therapy, whether the drug is dispensed via a vial or prefilled syringe. We are excited that this project includes a close collaboration between KORU and SCHOTT Pharma.”
About KORU Medical Systems
KORU Medical Systems develops, manufactures, and commercializes innovative and patient-centric large volume subcutaneous infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System (the “Freedom System”) currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. The Freedom System, which received its first FDA clearance in 1994, is used for self-administration in the home by the patient and/or delivery in an ambulatory infusion center by a healthcare professional. Through its Novel Therapies business, KORU Medical provides products for use by biopharmaceutical companies in feasibility/clinical trials during the drug development process and, as needed, is capable of customizing the Freedom System for clinical and commercial use across multiple drug categories. For more information, please visit www.korumedical.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, including but not limited to collaboration and future Company projects with SCHOTT. Actual results may differ materially from these statements due to potential risks and uncertainties such as those risks and uncertainties included under the captions "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023 which is on file with the SEC and available on our website at www.korumedical.com/investors and on the SEC website at www.sec.gov. All information provided in this release and in the attachments is as of February 6, 2025. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250206575340/en/
Investor Contact:
Louisa Smith
investor@korumedical.com
Source: KORU Medical Systems, Inc.
FAQ
What is the purpose of KORU Medical's new agreement for SCIg infusion system?
How will SCHOTT Pharma contribute to KRMD's new infusion system development?
What are the key features of KRMD's next-generation infusion system?
Will KRMD develop more projects with SCHOTT Pharma beyond this initial agreement?
